title: Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management.
abstract: Over the past decade, targeted therapies such as BRAF inhibitors, MEK inhibitors and immunotherapies such as anti-CTLA4 and anti-PD1 antibodies have emerged as novel treatments of advanced melanoma. Along with increased use of these therapies, a range of cutaneous adverse events have also emerged, varying from more serious and frequent cutaneous squamous cell carcinoma to mere cosmetic changes such as curly hair or rare severe toxic epidermal necrolysis. Early detection and management of these cutaneous adverse events will aid patients to receive accurate treatment, avoid unnecessary discontinuation of anti-tumour treatment and improve the patient's overall quality of life. This review will describe various cutaneous adverse events of anti-melanoma therapies and its management.
authors.affiliation: Department of Dermatology, Westmead Hospital, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia. Electronic address: shelley.hwang@hotmail.com.
authors.forename: S J E
authors.initials: SJ
authors.lastname: Hwang
authors.affiliation: Department of Dermatology, Westmead Hospital, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
authors.forename: R
authors.initials: R
authors.lastname: Anforth
authors.affiliation: Department of Dermatology, Westmead Hospital, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
authors.forename: G
authors.initials: G
authors.lastname: Carlos
authors.affiliation: Department of Dermatology, Westmead Hospital, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
authors.forename: P
authors.initials: P
authors.lastname: Fernandez-Peñas
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced; D003875:Drug Eruptions / Q000145:classification / Q000209:etiology* / Q000628:therapy; D004357:Drug Synergism; D006201:Hair Diseases / Q000139:chemically induced; D006801:Humans; D007642:Keratosis / Q000139:chemically induced; D008545:Melanoma / Q000188:drug therapy*; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D016609:Neoplasms, Second Primary / Q000139:chemically induced; D015434:Panniculitis / Q000139:chemically induced; D010787:Photosensitivity Disorders / Q000139:chemically induced; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011788:Quality of Life; D012878:Skin Neoplasms / Q000139:chemically induced / Q000188:drug therapy*; D014820:Vitiligo / Q000139:chemically induced
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D009363:Neoplasm Proteins; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D047428:Protein Kinase Inhibitors
keywords: Anti-CTLA4; Anti-Cytotoxic T-lymphocyte-associated protein 4; Anti-PD1; Anti-Programmed cell death-1; B-Raf inhibitors; Cutaneous adverse event; Efecto cutáneo adverso; Inhibidores de BRAF; Inhibidores de MEK; Melanoma metastásico; Metastatic melanoma; Mitogen-activated protein kinase inhibitor